Effect of age on serum prostate-specific antigen in women

Diamandis, Eleftherios P.; Eklund, Emma; Muytjens, Carla; Fiala, Clare; Wheeler, Sarah; Nikolenko, Galina N.; Mathew, Anu; Stengelin, Martin; Glezer, Eli N.; Brown, Marshall; Zheng, Yingye; Hirschberg, Angelica Lindén

doi:10.1515/cclm-2017-0150

Cited by 3 publications

(3 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With highly sensitive assays serum PSA concentrations may be measured also in women. Interestingly, as demonstrated by Diamandis et al [9] serum PSA concentration markedly decreases with age. Future studies will determine what role, if any, could PSA play in the management of cancers in women, e.g.…”

mentioning

confidence: 72%

See 1 more Smart Citation

Tumor microenvironment and systemic disease: a dual target in medical oncology (also in the case of biomarkers)

Melichar

2017

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

mentioning

confidence: 72%

“…The communication by Diamandis et al [9] introduces data that go beyond the traditional use of PSA. PSA is routinely assessed only in males.…”

mentioning

confidence: 99%

Tumor microenvironment and systemic disease: a dual target in medical oncology (also in the case of biomarkers)

Melichar

2017

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

“…In different age groups, PSA test results should be interpreted with caution. In contrast to men, there is an inverse correlation between the PSA level and age in women, and it is almost halved in each decade of life [64]. On the other hand, the study of Tokmak has shown that PSA levels in adolescents with PCOS do not differ significantly from healthy teens so PSA may be not a good diagnostic test in this age group.…”

Section: Discussionmentioning

confidence: 96%

Serum Prostate-Specific Antigen Level in Women With Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis

et al. 2019

View full text Add to dashboard Cite

We undertook a comprehensive search of all published original articles evaluating the diagnostic value of prostate-specific antigen (PSA) for the detection of polycystic ovary syndrome (PCOS). Finally, 25 studies with a total of 1865 participants (1104 cases and 761 controls) met the inclusion criteria. Mean serum PSA levels were significantly higher in PCOS women compared to healthy women [Standardized mean difference (SMD)=1.73 ng/ml, 95% CI=1.22 to 2.25, p<0.001]. Only 5 studies reported accuracy indicators and were included in the bivariate random-effects model; with a total of 509 samples that included 332 (65.22%) confirmed PCOS women. The sensitivity of serum PSA for the diagnosis of PCOS varied between 66.3 and 90.6%, and, the specificity ranged from 62.5–86.7%. Meta-analysis revealed a pooled sensitivity of 72.3% (95% CI 67.1–77.00%) and specificity of 74.6% (95% CI 67.5–80.8%) with an area under the summary ROC curve equal to 0.82 (95% CI 0.75–0.83). The summary estimates were 2.92 (95% CI 1.98–4.31) for positive LR and 0.37 (95% CI 0.26–0.51) for negative LR. The pooled estimate of diagnostic odds ratio (DOR) of serum PSA was 9.01 (95% CI 4.35–18.64). Considering the methodological weaknesses existed in studies, lack of sufficient data regarding the accuracy indicators, and the complexity of the exact pathophysiology of PSA secretion in women, the precise position of PSA, as a diagnostic test for the detection of PCOS, in clinical practice is undetermined, and further studies are still needed.

show abstract

Utility of a Fifth-Generation Ultrasensitive Prostate-Specific Antigen Assay for Monitoring Prostate Cancer Patients after Radical Prostatectomy with 3 Years of Follow-Up

et al. 2020

View full text Add to dashboard Cite

Background We investigated an ultrasensitive prostate-specific antigen (uPSA) immunoassay (MesoScale; lower limit of detection (LLD) of 0.0035 pg/mL) to monitor patients with prostate cancer (PCa) following radical prostatectomy (RP) and to examine whether changes in PSA in the conventionally undetectable range (<1 pg/mL) can predict biochemical relapse (BCR). Methods We measured uPSA in serial serum samples (N = 100) collected from 20 RP cases with a third-generation ELISA (LLD of 1 pg/mL) and the fifth-generation MesoScale assay. We analyzed the PSA nadir changes to classify patients into BCR or non-BCR groups, observed the trends in PSA kinetics, and associated BCR status with clinicohistopathological features. Results The ELISA could quantify PSA in only 38% of the RP samples, detecting BCR in 7 of 20 patients with PCa. The MesoScale assay quantified PSA in all samples, showing 8 of 20 patients with BCR. However, there was no significant difference between the median time to BCR detection based on ELISA (1016 days) compared with MesoScale data (949 days). Gleason scores were higher in the BCR groups compared with non-BCR. There was no significant difference for other clinicohistopathological parameters. Conclusions The uPSA MesoScale technology could track miniscule changes in serum PSA in the range of 0.003–1 pg/mL in all RP cases. However, PSA kinetics and nadir at concentrations <2 pg/mL fluctuated, and increases below this range could not reliably suggest signs of BCR. Instead, ultrasensitive fifth-generation PSA assays may hold clinical potential for measuring the low concentrations of PSA in women for various medical contexts.

show abstract

Effect of age on serum prostate-specific antigen in women

Cited by 3 publications

References 6 publications

Tumor microenvironment and systemic disease: a dual target in medical oncology (also in the case of biomarkers)

Tumor microenvironment and systemic disease: a dual target in medical oncology (also in the case of biomarkers)

Serum Prostate-Specific Antigen Level in Women With Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis

Utility of a Fifth-Generation Ultrasensitive Prostate-Specific Antigen Assay for Monitoring Prostate Cancer Patients after Radical Prostatectomy with 3 Years of Follow-Up

Contact Info

Product

Resources

About